FDA approval of Hibsago is a transformative pipeline event for GSK. Monitor initial prescription uptake, pricing/reimbursement decisions, and upcoming regulatory decisions in ex-US markets (China, EU). Competitor hepatitis B programs (e.g., from Arbutus, Gilead, Alnylam) may face increased pressure.
Price Chart
Executive Summary
GSK announced FDA approval of Hibsago (bepirovirsen) for chronic hepatitis B, a first-in-class antisense oligonucleotide that achieved 19% functional cure rates in phase III trials versus <1% for standard of care. This is a major pipeline catalyst for GSK, unlocking a new revenue stream in a large US market (~1.7 million patients) and validating its hepatology R&D strategy.
Key Facts
- FDA approved Hibsago (bepirovirsen) for chronic hepatitis B under priority review and Breakthrough Therapy Designation
- Phase III B-Well trials showed 19% functional cure rate (233/1,220) vs 0% placebo in patients with HBsAg ≤3000 IU/ml
- In patients with ≤1000 IU/ml HBsAg (≈45% of diagnosed cases), functional cure rate reached 26% (200/768)
- US chronic hepatitis B population estimated at approximately 1.7 million people
- Bepirovirsen is a first-in-class antisense oligonucleotide licensed from Ionis Pharmaceuticals
- Approval follows prior approval in Japan; regulatory submissions ongoing in other geographies
Financial Impact
No revenue or pricing disclosed; potential multi-billion-dollar peak sales opportunity given large addressable US CHB population and functional cure differentiation vs lifelong suppressive therapy
Risk Factors
- Commercial adoption depends on physician education, diagnostic testing adoption, and payer coverage for a finite-duration functional cure
- Safety monitoring required for injection site reactions and transient liver enzyme elevations
- Competing functional cure approaches in development could erode first-mover advantage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-009062 |
| Document: 0001654954-26-009062-index-headers.html | 0001654954-26-009062 |
| Document: 0001654954-26-009062-index.html | 0001654954-26-009062 |
| Document: 0001654954-26-009062.txt | 0001654954-26-009062 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $51.15 | awaiting T+1 | — | $51.10 (−0.10%) |
Oct 26, 2026 today | 6-K | $50.99 | awaiting T+1 | — | $51.10 (+0.22%) |
Oct 26, 2026 today | 6-K | $51.11 | awaiting T+1 | — | $51.10 (−0.02%) |
Oct 26, 2026 today | 6-K | $50.83 | awaiting T+1 | — | $51.10 (+0.53%) |
Oct 21, 2026 5d ago | 6-K | $50.02 $51.21 | ▲ +2.38% | ▲ +3.56% | $51.10 (+2.16%) |
Oct 19, 2026 7d ago | 6-K | $49.46 $50.63 | ▲ +2.37% | ▲ +2.03% | $51.10 (+3.32%) |
Oct 19, 2026 7d ago | 6-K | $49.46 $50.63 | ▲ +2.37% | ▲ +2.03% | $51.10 (+3.32%) |
Oct 15, 2026 11d ago | 6-K | $49.02 $49.51 | ▲ +1.00% | ▲ +2.11% | $51.10 (+4.24%) |
Oct 14, 2026 12d ago | 6-K | $47.87 $49.02 | ▲ +2.40% | ▲ +2.12% | $51.10 (+6.75%) |
Oct 13, 2026 13d ago | 6-K | $46.27 $47.87 | ▲ +3.46% | ▲ +4.54% | $51.10 (+10.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers